Tag: Agilent Technologies

Brown Shipley& Co Ltd increased its stake in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) by 7.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 29,206 shares of the medical research company’s stock after buying an additional 2,136 shares during the period. Agilent Technologies comprises 2.0% of Brown Shipley& Co Ltd’s portfolio, making the stock its 18th largest holding. Brown Shipley& Co Ltd’s holdings in Agilent Technologies were worth $4,061,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Blair William & Co. IL lifted its holdings in shares of Agilent Technologies by 1.9% in the third quarter. Blair William & Co. IL now owns 18,002 shares of the medical research company’s stock valued at $2,013,000 after purchasing an additional 334 shares in the last quarter. William Blair Investment Management LLC purchased a new position in shares of Agilent Technologies during the third quarter valued at approximately $662,000. PNC Financial Services Group Inc. lifted its stake in shares of Agilent Technologies by 5.7% during the third quarter. PNC Financial Services Group Inc. now owns 167,831 shares of the medical research company’s stock valued at $18,767,000 after buying an additional 9,099 shares during the period. Aviva PLC lifted its stake in shares of Agilent Technologies by 2.6% during the third quarter. Aviva PLC now owns 279,860 shares of the medical research company’s stock valued at $31,294,000 after buying an additional 7,155 shares during the period. Finally, Kestra Advisory Services LLC lifted its stake in shares of Agilent Technologies by 12.6% during the third quarter. Kestra Advisory Services LLC now owns 15,636 shares of the medical research company’s stock valued at $1,748,000 after buying an additional 1,749 shares during the period.

Insiders Place Their Bets

In other news, SVP Dominique Grau sold 15,000 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the sale, the senior vice president now owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, SVP Philip Binns sold 2,827 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $147.54, for a total value of $417,095.58. Following the completion of the transaction, the senior vice president now owns 9,997 shares of the company’s stock, valued at $1,474,957.38. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Dominique Grau sold 15,000 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $133.28, for a total value of $1,999,200.00. Following the completion of the transaction, the senior vice president now directly owns 49,486 shares of the company’s stock, valued at approximately $6,595,494.08. The disclosure for this sale can be found here. Insiders sold a total of 19,785 shares of company stock valued at $2,670,836 in the last quarter.

Agilent Technologies Trading Down 0.6 %

Shares of A stock opened at $129.85 on Monday. Agilent Technologies, Inc. has a 1 year low of $96.80 and a 1 year high of $155.35. The firm’s fifty day simple moving average is $140.91 and its 200 day simple moving average is $138.21. The firm has a market capitalization of $37.89 billion, a P/E ratio of 30.70, a price-to-earnings-growth ratio of 4.40 and a beta of 1.07. The company has a current ratio of 2.15, a quick ratio of 1.64 and a debt-to-equity ratio of 0.34.

Agilent Technologies (NYSE:A – Get Free Report) last issued its earnings results on Wednesday, May 29th. The medical research company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.19 by $0.03. The company had revenue of $1.57 billion for the quarter, compared to the consensus estimate of $1.58 billion. Agilent Technologies had a net margin of 18.84% and a return on equity of 26.25%. The firm’s revenue for the quarter was down 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.27 EPS. As a group, sell-side analysts predict that Agilent Technologies, Inc. will post 5.25 EPS for the current year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 24th. Shareholders of record on Tuesday, July 2nd will be given a dividend of $0.236 per share. This represents a $0.94 dividend on an annualized basis and a yield of 0.73%. The ex-dividend date is Tuesday, July 2nd. Agilent Technologies’s dividend payout ratio (DPR) is currently 22.22%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on A shares. Oppenheimer increased their price objective on shares of Agilent Technologies from $67.00 to $90.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 26th. UBS Group dropped their price objective on shares of Agilent Technologies from $155.00 to $141.00 and set a “neutral” rating for the company in a research report on Thursday, May 30th. Robert W. Baird decreased their target price on shares of Agilent Technologies from $147.00 to $136.00 and set an “outperform” rating for the company in a research note on Thursday, May 30th. Evercore ISI decreased their target price on shares of Agilent Technologies from $145.00 to $126.00 and set an “in-line” rating for the company in a research note on Thursday, May 30th. Finally, Citigroup decreased their target price on shares of Agilent Technologies from $145.00 to $135.00 and set a “neutral” rating for the company in a research note on Thursday, May 30th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and ten have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $136.50.

Check Out Our Latest Report on Agilent Technologies

Agilent Technologies Company Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.

Featured Articles

Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies, Inc. (NYSE:A – Free Report).

Receive News & Ratings for Agilent Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Agilent Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.

Putnam Investments LLC cut its stake in shares of Agilent Technologies, Inc. (NYSE:A – Free Report) by 10.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,106 shares of the medical research company’s stock after selling 2,879 shares during the period. Putnam Investments LLC’s holdings in Agilent Technologies were worth $3,335,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Synovus Financial Corp increased its holdings in Agilent Technologies by 2.3% in the first quarter. Synovus Financial Corp now owns 6,751 shares of the medical research company’s stock valued at $895,000 after purchasing an additional 153 shares during the period. Blair William & Co. IL boosted its position in Agilent Technologies by 7.3% during the first quarter. Blair William & Co. IL now owns 28,606 shares of the medical research company’s stock valued at $3,785,000 after acquiring an additional 1,957 shares during the last quarter. Sequoia Financial Advisors LLC boosted its position in Agilent Technologies by 52.1% during the first quarter. Sequoia Financial Advisors LLC now owns 2,334 shares of the medical research company’s stock valued at $309,000 after acquiring an additional 799 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Agilent Technologies by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 24,531,170 shares of the medical research company’s stock worth $3,246,209,000 after purchasing an additional 261,435 shares in the last quarter. Finally, Zions Bancorporation N.A. boosted its position in shares of Agilent Technologies by 10.8% during the 1st quarter. Zions Bancorporation N.A. now owns 2,880 shares of the medical research company’s stock worth $381,000 after purchasing an additional 281 shares in the last quarter.

Agilent Technologies Trading Up 0.9 %

Shares of A opened at $115.91 on Monday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 1.68 and a current ratio of 2.29. Agilent Technologies, Inc. has a fifty-two week low of $109.00 and a fifty-two week high of $160.26. The firm has a 50 day moving average price of $121.61 and a 200-day moving average price of $126.47. The firm has a market cap of $33.91 billion, a price-to-earnings ratio of 30.34, a PEG ratio of 2.09 and a beta of 1.03.

Agilent Technologies (NYSE:A – Get Free Report) last posted its quarterly earnings results on Tuesday, August 15th. The medical research company reported $1.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.36 by $0.07. The business had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.66 billion. Agilent Technologies had a net margin of 16.20% and a return on equity of 29.86%. The company’s revenue was down 2.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.34 earnings per share. As a group, equities research analysts forecast that Agilent Technologies, Inc. will post 5.42 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on A. 888 reissued a “maintains” rating on shares of Agilent Technologies in a research report on Wednesday, May 24th. Jefferies Financial Group dropped their target price on Agilent Technologies from $150.00 to $146.00 and set a “buy” rating on the stock in a report on Wednesday, August 16th. SVB Securities lowered their target price on shares of Agilent Technologies from $170.00 to $145.00 and set an “outperform” rating for the company in a report on Wednesday, May 24th. Stifel Nicolaus decreased their price target on Agilent Technologies from $153.00 to $135.00 and set a “hold” rating for the company in a research report on Wednesday, May 24th. Finally, Credit Suisse Group reduced their price objective on Agilent Technologies from $160.00 to $150.00 and set an “outperform” rating for the company in a research note on Wednesday, August 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $148.12.

View Our Latest Stock Analysis on A

Insiders Place Their Bets

In other news, CEO Michael R. Mcmullen sold 944 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $130.00, for a total transaction of $122,720.00. Following the completion of the sale, the chief executive officer now owns 260,869 shares of the company’s stock, valued at $33,912,970. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Michael R. Mcmullen sold 944 shares of the stock in a transaction that occurred on Thursday, July 27th. The stock was sold at an average price of $130.00, for a total transaction of $122,720.00. Following the completion of the sale, the chief executive officer now owns 260,869 shares of the company’s stock, valued at $33,912,970. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Rodney Gonsalves sold 3,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $118.78, for a total value of $415,730.00. Following the transaction, the vice president now owns 24,219 shares of the company’s stock, valued at approximately $2,876,732.82. The disclosure for this sale can be found here.

Agilent Technologies Profile

(Free Report)

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies.

Featured Articles

Receive News & Ratings for Agilent Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Agilent Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.